tradingkey.logo

Aytu BioPharma Q2 revenue beats expectations

ReutersFeb 3, 2026 9:21 PM


Overview

  • Pharmaceutical company's Q2 revenue beat analyst expectations

  • Adjusted EBITDA for Q2 beat analyst expectations


Outlook

  • Company did not provide specific financial guidance for future quarters or full year in press release


Result Drivers

  • SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA

  • INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$15.17 mln

$12.17 mln (3 Analysts)

Q2 Net Income

-$10.58 mln

Q2 Adjusted EBITDA

Beat

-$800,000

-$4.30 mln (3 Analysts)

Q2 Gross Profit

$9.62 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71

Press Release: ID:nACStMvP3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI